PY-4Car2 

PY-4Car2 is a Camptothecin (HY-16560) derivative and a topoisomerase I inhibitor. PY-4Car2 functions as a warhead conjugated via a cleavable linker to the bispecific ADC TJ101. PY-4Car2 can be used as an ADC payload for the research of cancers^[1][2]_.

PY-4CAR2, when delivered via the bispecific dual-payload ADC TJ102 (co-formulated with PE-E2K), contributes to robust, selective cytotoxicity in ovarian and kidney cancer cell lines^[1].
PY-4Car2, as the warhead of bispecific ADC TJ101, drives synergistic cytotoxicity in EGFR- and B7-H3-coexpressing solid cancer cell lines, with activity dependent on target antigen binding^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

551.56

C₂₉H₃₀FN₃O₇

3054643-04-5

OCCCCOC(N[C@@H]1C2=C3C(C(N4C3)=CC([C@](O)(C(OC5)=O)CC)=C5C4=O)=NC6=CC(F)=C(C)C(CC1)=C62)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yangxin Zhang, et al. Abstract LB021: TJ102: A promising bispecific dual-payload ADC targeting CDH6 and folate receptor alpha (FRα) for the treatment of ovarian and kidney cancers. Cancer Res (2025) 85 (8_Supplement_2): LB021.

  [2]. Li Qi, et al. Abstract 2955: Preclinical development of TJ101, a potent bispecific ADC targeting EGFR and B7-H3 for the treatment of solid cancers. Cancer Res (2025) 85 (8_Supplement_1): 2955.